- Anteo Diagnostics is an Australian biotechnology company that develops proprietary surface coatings called Mix&Go for use in healthcare, life sciences, and other industries. - Mix&Go is a universal double-sided molecular coating that gently but strongly binds biomolecules to synthetic surfaces, addressing challenges in test miniaturization and cost reduction. - Anteo's growth strategy includes licensing its intellectual property, expanding its coating technologies and applications, developing product pipelines that demonstrate Mix&Go's uses, exploring new market opportunities, and acquiring synergistic assets.

1. Anteo Diagnostics Limited (ASX:ADO)
March 2015
Presented by
Dr Geoff Cumming
CEO

2. Forward Looking Statement
The purpose of the presentation is to provide an update of the business of Anteo Diagnostics (ASX:ADO).
These slides have been prepared as a presentation aid only and the information they contain may require
further explanation and/or clarification. Accordingly, these slides and the information they contain should be
read in conjunction with past and future announcements made by Anteo and should not be relied upon as an
independent source of information. Please contact Anteo and/or refer to the Company's website for further
information.
The views expressed in this presentation contain information derived from publicly available sources that
have not been independently verified. No representation or warranty is made as to the accuracy,
completeness or reliability of the information.
Any forward looking statements in this presentation have been prepared on the basis of a number of
assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about
future events are subject to risks, uncertainties and other factors, many of which are outside Anteo
Diagnostics Ltd ’s control. Important factors that could cause actual results to differ materially from
assumptions or expectations expressed or implied in this presentation include known and unknown risks.
Because actual results could differ materially to assumptions made and Anteo’s current intentions, plans,
expectations and beliefs about the future, you are urged to view all forward looking statements contained in
this presentation with caution.
This presentation should not be relied on as a recommendation or forecast by Anteo Diagnostics Limited.
Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or
sell shares in any jurisdiction.
Anteo Diagnostics Limited I Investor Presentation 2

3. Anteo Company Profile
An Australian biotechnology company that develops,
manufactures and commercialises proprietary surface coatings
for health care, life sciences and beyond.
Anteo Diagnostics Limited I Investor Presentation 3
Mix&Go™
BiosensorsMembranes Microarrays Microtitre
plates
Particles
The surface you want on the surface you have.

4. Financial Snapshot – March 2015
Executive Team
Dr. Geoff Cumming – Chief Executive Officer
Dr. Joe Maeji – Chief Scientific Officer
Mr. Richard Martin – Chief Financial Officer
Dr. Tina Baumgartner – VP of Business Development
Mr. Joshua Soldo – VP of ScientificAffairs
Dr Rachel de las Heras – Head Commercial Development
Mr. Shaun Cooper – Head of Production
Board of Directors
Mr. Mark Bouris
Non-Executive Chairman
Dr. Geoff Cumming
Chief Executive Officer
Mr. Richard Martin
Executive Director
Ms. Sandra Andersen
Non-Executive Director
Dr. John Hurrell
Non-Executive Director
Anteo Diagnostics Limited I Investor Presentation 4
Shareholders 5,019
First Cape Mgt Pty Ltd 9.4%
Austcorp 190 Pty Ltd 3.9%
Nimrod Finance Ltd 2.4%
Corporate Snapshot
ASX ADO
Cash $6.8M
Market Cap. $78M
Av Daily Volume (30 d) 1,378,989
52 week high/low $0.28/$0.09
Shares on issue 844.8M
Top 20 29.78%
Directors/Staff 16%

5. Diagnostic Industry Drivers
Health Economics Point-of-Care Testing
PERCENT OF WW
HEALTHCARE SPENDING
USED ON DIAGNOSTICS
PERCENT OF MEDICAL
DECISION-MAKING
INFLUENCED BY DIAGNOSTICS
DIAGNOSTIC TESTING MOVES
FROM THE LABORATORY
TO THE POINT OF CARE
2% 70%
Diagnostics = critical medical decision-making
• better patient outcomes
• lives saved
• reduced health care costs
Diagnostic test are moving closer to the:
• patient
• physician’s office
• emergency vehicles
• assisted living facilities
• patient’s home
Anteo Diagnostics Limited I Investor Presentation 6
Cost Savings Miniaturisation

6. Mix&Go-The Secret Sauce
Anteo Diagnostics Limited I Investor Presentation 6
• Ease of use
• Performance
• Cost
• Manufacturability
Improves what’s possible; and makes the
impossible accessible

7. Platform Technology: Mix&Go Value Creation
Mix&Go™ is a universal double-sided molecular velcro:
The Mix&Go Difference
Anteo Diagnostics Limited I Investor Presentation 5
• Uniquely suited for applications in diagnostics and life sciences
• Binds fragile biomolecules gently yet strongly to synthetic surfaces
• Addresses critical bottlenecks in test development:
• Miniaturisation for point-of-care
• Pressure to save cost in test development and manufacture
• Family of products, over 50 formulations for different applications

8. Value Capture
Anteo participates in the value it creates to its partners.
The company has different revenue streams:
Value
Creation
Licensing:
• Development Fees
• License or Technology Access Fees
• Royalties on sales from products containing Mix&Go
Value
Capture
R&D Agreements:
• Paid R&D undertaken on partner’s behalf
OEM and Supply Agreements:
• In house manufacture of Mix&Go-enhanced products
• For B2B customers
AMG Products and Services:
• Sales revenues
• Provide easy way to experience the Mix&Go advantages
• Provides partner with access to broad technical expertise
Anteo Diagnostics Limited I Investor Presentation 8

9. Growth Strategy
Anteo Diagnostics Limited I Investor Presentation 6
Anteo is implementing a five part growth strategy:
• Licensing Anteo’s IP
• Expanding Anteo’s Core Competencies & IP
• Developing Anteo’s Product Pipeline
• Exploring Anteo’s Blue Sky Opportunities
• Acquisition of Synergistic Assets
Shareholder Value

10. Licensing Anteo’s IP - Example – PoC Device
Breathing life into a challenging project …
•
•
•
•
•
•
•
•
•
•
Global, well-known diversified company (2013 healthcare revenues: €10B)
Initial application: critical care – cardiac function
Six years in development
Clinically necessary performance not achieved
Pilot study with Mix&Go showed promise
12 month paid engagement to optimize one of two
Achieved clinical benchmark
system components
Demonstrated significant improvement on second component
Now engaged in paid project to optimize system holistically
Projected launch: 2015
Expectation: royalties on every test performed on the instrument
Anteo Diagnostics Limited I Investor Presentation 9

11. Licensing IP - Anteo’s Future Opportunities
Large global healthcare markets underpin revenue growth
potential
Anteo is targeting a number of diverse large and growing healthcare sectors
with Mix&Go. The compelling market opportunities include:
• Bioseparations
• Laboratory Diagnostics
• Point-of-Care
• Rapid Test Products
• Life Science R&D
The total market size of these fields is in excess of $50B
Anteo Diagnostics Limited I Investor Presentation 10

12. Expanding Anteo’s Core Competencies & IP
Anteo Diagnostics Limited I Investor Presentation 10
AIM – To coat any surface in any format
1. Particles
ü Control protein density & particle uniformity
ü Especially Nanoparticles (< 1 µm and specialising in <100 nm)
2. Planar Surfaces
ü Coat common surfaces used in life sciences regardless of hydrophobicity/
hydrophilicity profile
3. Mix&Go Library
ü 25-50 new formulations
ü Mix&Go for hydrophobic surfaces
ü Cheaper Mix&Go for industrial applications
ü Safer Mix&Go for in-vivo applications
Competencies together support Licensing & Blue Sky applications

13. Expanding Anteo’s Core Competencies & IP
Anteo Diagnostics Limited I Investor Presentation 10
Level 1: Positioning
Level 2: Developing Core Competency (IP and Know How)
IP Strategy
ü Generation of Surface Coating Diversity. Granted.
Ø Methods to generate libraries of different surfaces and screening thereof
ü Use of Metal Complexes. Granted and US Divisional filed.
Ø Use of metal complexes to bind proteins to surfaces
ü Binding Systems. National Phase.
Ø Use of metal polymers as coatings
ü Method to remove or decrease interference in a sample.
ü PoC1 sensor surface could further improve outcomes with the device.
ü Coating Nanoparticles.
Ø Conjugating Molecules to Particles. PCT Phase.
ü Coating New Materials: new thermoplastics, steel, etc.
Ø Heterofunctional Binding Systems. Provisional Phase.

14. Developing Anteo’s Product Pipeline
Anteo Diagnostics Limited I Investor Presentation 10
AIM – To demonstrate stable and effective products can be
made and sold on the Mix&Go surface
1. Mix&Go Solutions
ü Mix&Go Sub-micron, Micro and Biosensor
ü Mix&Go Plates & Mix&Go In-Vivo
2. Novel Mix&Go products
ü AMG - Streptavidin coated plates and magnetic particles
ü AMG – Coupling Kit (magnetic beads 1 µm)
ü AMG – Activation Kit (latex particles 100-400 nm)
ü AMG – Coupling Kit (gold particles 40 nm)
ü AMG - Protein A/G/L Filtration Plate (bio-separations)
Builds technology and brand awareness. $$ & knowledge
acquired supports Core Competencies & Licensing

15. Exploring Anteo’s Blue Sky Opportunities
Anteo Diagnostics Limited I Investor Presentation 10

16. Exploring Anteo’s Blue Sky Opportunities
Not one market but multiple multi-billion $ markets
Attractive opportunities exist for Anteo
• Several applications in cleantech and resources under evaluation in
collaboration with domain experts.
Anteo Diagnostics Limited I Investor Presentation 10
Bioseparations:
Ø Purification of a biological material from mixture
Ø Mix&Go can bind to:
• bacteria, viruses, toxic metals, various
capture agents
Ø Combined with:
• Simple, cost effective magnetic separations
and membrane technologies.
Purification:
Water treatment, recycling oils, removing radio-isotopes
In Vivo:
Ø Scaffolds (bone, artery, cartilage
replacement)
Ø Wound dressings (sealants, artificial
membranes)
Ø Drug delivery (drug eluting stents)
Ø Implants (TiO2, IrO2 used as coatings
on vascular stents)

17. Acquisition of Synergistic Assets
Anteo Diagnostics Limited I Investor Presentation 10
Anteo is investigating the acquisition of companies that will
help act as a catalyst for commercialisation of Mix&Go.
Three key criteria:
ü Cash Flow Positive
ü Accretive and
ü Technological Fit
Advisor appointed – reviewing opportunities

18. Planned Milestones for 2015
2015 2016
Anteo Diagnostics Limited I Investor Presentation 11
Advancing near-term value accretive opportunities that will translate
quickly into revenue….
ü Feasibility agreement w/ global healthcare company for development of Point of Care device
ü Entered into a paid Research and Collaboration Agreement with IMRA
ü Strengthening existing partner relations by co-developing and co-marketing products
ü Negotiations advancing with medical device company, extending our opportunities into in Vivo
ü Two additional paid Research and Collaboration projects undertaken during the Q1 of CY 2015
ü Mix&Go integrated in 100+ products at partner company
ü Continue to launch 1 product/ quarter
ü Adding distribution partners for Anteo’s Mix&Go and AMG product lines
ü Advancing a proprietary product concept with large industry-wide potential
ü Generating custom M&G formulations optimized for various surfaces and applications
ü New patent application continues to build Anteo’s suite of patents using Mix&Go
Ø Latest application builds on previously filed patents and strengthens our IP position
Anteo has several projects in advanced development and adds to its deal pipeline continuously

19. Anteo is set up for Growth
Anteo Diagnostics Limited I Investor Presentation 11
• Mix&Go is a proprietary platform technology with broad applicability in
diagnostics, life sciences, bioseparations and beyond
• Mix&Go is proven, licensed and gaining significant traction in commercial
markets
• Mix&Go products provide easy access and credibility for customers
• Strong near term value drivers
• Focus on diagnostics and life sciences with expansion into bioseparations
provides Anteo significant revenue opportunities
• Ready to develop opportunities in additional markets and execute long term
potential
• Strong leadership - Board and management team in place to drive growth
• Global team, resources and network to capitalise on growth opportunities

20. Contact Information
Thank you very much for you interest in Anteo Diagnostics
For more information please contact:
Anteo Diagnostics Limited I Investor Presentation 13
Dr.
Geoff
Cumming,
CEO
E:
geoff.cumming@anteodx.com
M:
+61
417
203
021
Or download Anteo Investor
Relations App for latest ASX news,
share price and important company
updates.
Available under Anteo IR at App store and Google play